Breaking News
Get 40% Off 0
🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For Free Copy Portfolio
Close

Ono Pharmaceutical Co Ltd (OPHLY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4.77 +0.14    +3.02%
31/05 - Closed. Currency in USD ( Disclaimer )
After Hours
4.78
+0.01
+0.21%
21:09:14 - Delayed Data
  • Volume: 180,644
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 4.65 - 4.78
Type:  Equity
Market:  United States
Ono Pharmaceutical Co 4.77 +0.14 +3.02%

OPHLY Income Statement & Profits

 
Assess the Ono Pharmaceutical Co Ltd income statement, view the company's financial performance across their assets and liabilities. Select to view either quarterly or annual data.
AnnualQuarterly
Advanced Income Statement
Period Ending: 2024
31/03
2023
31/12
2023
30/09
2023
30/06
Total Revenue 112769 131190 138697 120016
Revenue 112769 131190 138697 120016
Other Revenue, Total - - - -
Cost of Revenue, Total 31664 30697 34594 30171
Gross Profit 81105 100493 104103 89845
Total Operating Expenses 97459 83601 83009 78668
Selling/General/Admin. Expenses, Total 26975 25691 24121 23483
Research & Development 35681 27133 24781 24579
Depreciation / Amortization 4711 4343 4556 4530
Interest Expense (Income) - Net Operating - -394 - -241
Unusual Expense (Income) - - - -
Other Operating Expenses, Total -1572 -3157 -5023 -3854
Operating Income 15310 47589 55688 41348
Interest Income (Expense), Net Non-Operating - - - -
Gain (Loss) on Sale of Assets - - - -
Other, Net -1131 -407 -1230 -1030
Net Income Before Taxes 16441 47996 56918 42378
Provision for Income Taxes -988 11906 14216 10560
Net Income After Taxes 17429 36090 42702 31818
Minority Interest 5644 6023 5998 5961
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items 17433 36053 42673 31818
Total Extraordinary Items - - - -
Net Income 17433 36052 42673 31818
Total Adjustments to Net Income - - - -
Income Available to Common Excluding Extraordinary Items 17433 36053 42673 31818
Dilution Adjustment 5 4 -0.476 1.09
Diluted Net Income 17428 36048 42673.48 31816.91
Diluted Weighted Average Shares 472.44 475.84 483.94 488.36
Diluted EPS Excluding Extraordinary Items 36.89 75.76 88.18 65.15
DPS - Common Stock Primary Issue 40 - 40 -
Diluted Normalized EPS 21.76 62.96 73.45 54.23
* In Millions of JPY (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

OPHLY Price Commentary

Write your thoughts about Ono Pharmaceutical Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email